Cargando…

Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge

Current influenza vaccines demonstrate low vaccine efficacy, especially when the predominantly circulating strain and vaccine are mismatched. The novel influenza vaccine platform M2- or BM2-deficient single replication (M2SR and BM2SR) has been shown to safely induce strong systemic and mucosal anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill-Batorski, Lindsay, Hatta, Yasuko, Moser, Michael J., Sarawar, Sally, Neumann, Gabriele, Kawaoka, Yoshihiro, Bilsel, Pamuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142185/
https://www.ncbi.nlm.nih.gov/pubmed/37112710
http://dx.doi.org/10.3390/vaccines11040798
_version_ 1785033553728241664
author Hill-Batorski, Lindsay
Hatta, Yasuko
Moser, Michael J.
Sarawar, Sally
Neumann, Gabriele
Kawaoka, Yoshihiro
Bilsel, Pamuk
author_facet Hill-Batorski, Lindsay
Hatta, Yasuko
Moser, Michael J.
Sarawar, Sally
Neumann, Gabriele
Kawaoka, Yoshihiro
Bilsel, Pamuk
author_sort Hill-Batorski, Lindsay
collection PubMed
description Current influenza vaccines demonstrate low vaccine efficacy, especially when the predominantly circulating strain and vaccine are mismatched. The novel influenza vaccine platform M2- or BM2-deficient single replication (M2SR and BM2SR) has been shown to safely induce strong systemic and mucosal antibody responses and provide protection against significantly drifted influenza strains. In this study, we demonstrate that both monovalent and quadrivalent (Quad) formulations of M2SR are non-pathogenic in mouse and ferret models, eliciting robust neutralizing and non-neutralizing serum antibody responses to all strains within the formulation. Following challenge with wildtype influenza strains, vaccinated mice and ferrets demonstrated reduced weight loss, decreased viral replication in the upper and lower airways, and enhanced survival as compared to mock control groups. Mice vaccinated with H1N1 M2SR were completely protected from heterosubtypic H3N2 challenge, and BM2SR vaccines provided sterilizing immunity to mice challenged with a cross-lineage influenza B virus. Heterosubtypic cross-protection was also seen in the ferret model, with M2SR vaccinated animals exhibiting decreased viral titers in nasal washes and lungs following the challenge. BM2SR-vaccinated ferrets elicited robust neutralizing antibodies toward significantly drifted past and future influenza B strains. Mice and ferrets that received quadrivalent M2SR were able to mount immune responses equivalent to those seen with each of the four monovalent vaccines, demonstrating the absence of strain interference in the commercially relevant quadrivalent formulation.
format Online
Article
Text
id pubmed-10142185
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101421852023-04-29 Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge Hill-Batorski, Lindsay Hatta, Yasuko Moser, Michael J. Sarawar, Sally Neumann, Gabriele Kawaoka, Yoshihiro Bilsel, Pamuk Vaccines (Basel) Article Current influenza vaccines demonstrate low vaccine efficacy, especially when the predominantly circulating strain and vaccine are mismatched. The novel influenza vaccine platform M2- or BM2-deficient single replication (M2SR and BM2SR) has been shown to safely induce strong systemic and mucosal antibody responses and provide protection against significantly drifted influenza strains. In this study, we demonstrate that both monovalent and quadrivalent (Quad) formulations of M2SR are non-pathogenic in mouse and ferret models, eliciting robust neutralizing and non-neutralizing serum antibody responses to all strains within the formulation. Following challenge with wildtype influenza strains, vaccinated mice and ferrets demonstrated reduced weight loss, decreased viral replication in the upper and lower airways, and enhanced survival as compared to mock control groups. Mice vaccinated with H1N1 M2SR were completely protected from heterosubtypic H3N2 challenge, and BM2SR vaccines provided sterilizing immunity to mice challenged with a cross-lineage influenza B virus. Heterosubtypic cross-protection was also seen in the ferret model, with M2SR vaccinated animals exhibiting decreased viral titers in nasal washes and lungs following the challenge. BM2SR-vaccinated ferrets elicited robust neutralizing antibodies toward significantly drifted past and future influenza B strains. Mice and ferrets that received quadrivalent M2SR were able to mount immune responses equivalent to those seen with each of the four monovalent vaccines, demonstrating the absence of strain interference in the commercially relevant quadrivalent formulation. MDPI 2023-04-04 /pmc/articles/PMC10142185/ /pubmed/37112710 http://dx.doi.org/10.3390/vaccines11040798 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hill-Batorski, Lindsay
Hatta, Yasuko
Moser, Michael J.
Sarawar, Sally
Neumann, Gabriele
Kawaoka, Yoshihiro
Bilsel, Pamuk
Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge
title Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge
title_full Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge
title_fullStr Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge
title_full_unstemmed Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge
title_short Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge
title_sort quadrivalent formulation of intranasal influenza vaccine m2sr (m2-deficient single replication) protects against drifted influenza a and b virus challenge
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142185/
https://www.ncbi.nlm.nih.gov/pubmed/37112710
http://dx.doi.org/10.3390/vaccines11040798
work_keys_str_mv AT hillbatorskilindsay quadrivalentformulationofintranasalinfluenzavaccinem2srm2deficientsinglereplicationprotectsagainstdriftedinfluenzaaandbviruschallenge
AT hattayasuko quadrivalentformulationofintranasalinfluenzavaccinem2srm2deficientsinglereplicationprotectsagainstdriftedinfluenzaaandbviruschallenge
AT mosermichaelj quadrivalentformulationofintranasalinfluenzavaccinem2srm2deficientsinglereplicationprotectsagainstdriftedinfluenzaaandbviruschallenge
AT sarawarsally quadrivalentformulationofintranasalinfluenzavaccinem2srm2deficientsinglereplicationprotectsagainstdriftedinfluenzaaandbviruschallenge
AT neumanngabriele quadrivalentformulationofintranasalinfluenzavaccinem2srm2deficientsinglereplicationprotectsagainstdriftedinfluenzaaandbviruschallenge
AT kawaokayoshihiro quadrivalentformulationofintranasalinfluenzavaccinem2srm2deficientsinglereplicationprotectsagainstdriftedinfluenzaaandbviruschallenge
AT bilselpamuk quadrivalentformulationofintranasalinfluenzavaccinem2srm2deficientsinglereplicationprotectsagainstdriftedinfluenzaaandbviruschallenge